Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30
   PubMed Web of Science ®Google Scholar
• Simard EP, Ward EM, Siegel R, et al. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012. [ Epub ahead of print]
   PubMedGoogle Scholar
• Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27(17):2758-65
   PubMed Web of Science ®Google Scholar
• Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012;118(9):2338-66
   PubMed Web of Science ®Google Scholar
• Wörmann SM, Algül H. Risk factors and therapeutic targets in pancreatic cancer. Front Oncol 2013;3:282
   PubMedGoogle Scholar
• Li J, Ng J, Allendorf J, Saif MW. Locally advanced pancreatic adenocarcinoma: are we making progress?. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP 2011;12(4):347-50
   PubMedGoogle Scholar
• Carpelan-Holmström M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005;54(3):385-7
   PubMed Web of Science ®Google Scholar
• Kern SE, Shi C, Hruban RH. The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J Pathol 2011;223(2):295-306
   PubMed Web of Science ®Google Scholar
• Wolfgang CL, Corl F, Johnson PT, et al. Pancreatic surgery for the radiologist, 2011: an illustrated review of classic and newer surgical techniques for pancreatic tumor resection. AJR Am J Roentgenol 2011;197(6):1343-50
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP. Adjuvant treatment of pancreatic cancer. Eur J Cancer 2011;47(Suppl 3):S378-80
   Google Scholar
• Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350(12):1200-10
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25(15):1960-6
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817-25
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691-703
   PubMed Web of Science ®Google Scholar
• Adrian TE. Role of hormones and cytokines in insulin resistance and cachexia associated with pancreatic cancer. Eaton Pub Co; 1998
   Google Scholar
• Nixon DW, Lawson DH, Kutner M, et al. Hyperalimentation of the cancer patient with protein-calorie undernutrition. Cancer Res 1981;41(6):2038-45
   PubMed Web of Science ®Google Scholar
• Cohn SH, Vartsky D, Vaswani AN, et al. Changes in body composition of cancer patients following combined nutritional support. Nutr Cancer 1982;4(2):107-19
   PubMedGoogle Scholar
• Silverman DT, Schiffman M, Everhart J, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999;80(11):1830-7
   PubMed Web of Science ®Google Scholar
• Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer 2007;96(3):507-9
   PubMed Web of Science ®Google Scholar
• Bao Y, Michaud DS, Spiegelman D, et al. Folate intake and risk of pancreatic cancer: pooled analysis of prospective cohort studies. J Natl Cancer Inst 2011;103(24):1840-50
   PubMed Web of Science ®Google Scholar
• Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 2011;47(13):1928-37
   PubMed Web of Science ®Google Scholar
• Permert J, Ihse I, Jorfeldt L, et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993;159(2):101-7
   PubMedGoogle Scholar
• Gullo L, Pezzilli R, Morselli-Labate AM, et al. Diabetes and the risk of pancreatic cancer. N Engl J Med 1994;331(2):81-4
   PubMed Web of Science ®Google Scholar
• Hjalgrim H, Frisch M, Ekbom A, et al. Cancer and diabetes – a follow-up study of two population-based cohorts of diabetic patients. J Intern Med 1997;241(6):471-5
   PubMed Web of Science ®Google Scholar
• Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10(1):88-95
   PubMed Web of Science ®Google Scholar
• Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008;134(4):981-7
   PubMed Web of Science ®Google Scholar
• Permert J, Ihse I, Jorfeldt L, et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993;80(8):1047-50
   PubMed Web of Science ®Google Scholar
• Fogar P, Pasquali C, Basso D, et al. Diabetes mellitus in pancreatic cancer follow-up. Anticancer Res 1994;14(6B):2827-30
   PubMed Web of Science ®Google Scholar
• White MA, Agle SC, Fuhr HM, et al. Impact of pancreatic cancer and subsequent resection on glycemic control in diabetic and nondiabetic patients. Am Surg 2011;77(8):1032-7
   PubMed Web of Science ®Google Scholar
• Williams JA, Goldfine ID. The insulin-acinar relationship. In: Go VLW, editor. The pancreas: biology, pathobiology and disease. 2nd edition. Raven Press, New York; 1993. p. 789-802
   Google Scholar
• Ding XZ, Fehsenfeld DM, Murphy LO, et al. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas 2000;21(3):310-20
   PubMed Web of Science ®Google Scholar
• Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137(2):482-8
   PubMed Web of Science ®Google Scholar
• Sadeghi N, Abbruzzese JL, Yeung SC, et al. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012;18(10):2905-12
   PubMed Web of Science ®Google Scholar
• Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001;120(5):1263-70
   PubMed Web of Science ®Google Scholar
• Hwang AL, Haynes K, Hwang WT, et al. Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas 2013;42(7):1054-9
   PubMed Web of Science ®Google Scholar
• Zhang P, Li H, Tan X, et al. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 2013;37(3):207-18
   PubMed Web of Science ®Google Scholar
• Singh S, Singh PP, Singh AG, et al. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol 2013;108(4):510-19; quiz 520
   PubMed Web of Science ®Google Scholar
• Kisfalvi K, Eibl G, Sinnett-Smith J, et al. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009;69(16):6539-45
   PubMed Web of Science ®Google Scholar
• Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 2010;16(9):2505-11
   PubMed Web of Science ®Google Scholar
• Gou S, Cui P, Li X, et al. Low concentrations of metformin selectively inhibit CD133+ cell proliferation in pancreatic cancer and have anticancer action. PLoS One 2013;8(5):e63969
   PubMed Web of Science ®Google Scholar
• Lonardo E, Cioffi M, Sancho P, et al. Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One 2013;8(10):e76518
   Google Scholar
• Mohammed A, Janakiram NB, Brewer M, et al. Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl Oncol 2013;6(6):649-59
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ogo A, Yamura M, et al. Metformin suppresses sonic hedgehog expression in pancreatic cancer cells. Anticancer Res 2014;34(4):1765-9
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3(7):730-7
   PubMed Web of Science ®Google Scholar
• Valent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012;12(11):767-75
   PubMed Web of Science ®Google Scholar
• Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67(3):1030-7
   PubMed Web of Science ®Google Scholar
• Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1(3):313-23
   PubMed Web of Science ®Google Scholar
• Zhang GN, Liang Y, Zhou LJ, et al. Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. Cancer Lett 2011;313(2):137-44
   PubMed Web of Science ®Google Scholar
• Nusse R. Wnt signaling and stem cell control. Cell Res 2008;18(5):523-7
   PubMed Web of Science ®Google Scholar
• Sachlos E, Risueño RM, Laronde S, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012;149(6):1284-97
   PubMed Web of Science ®Google Scholar
• Rattan R, Ali Fehmi R, Munkarah A. Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol 2012;2012:928127
   Google Scholar
• Rizos CV, Elisaf MS. Metformin and cancer. Eur J Pharmacol 2013;705(1-3):96-108
   PubMed Web of Science ®Google Scholar
• Li Y, Maitah MY, Ahmad A, et al. Targeting the Hedgehog signaling pathway for cancer therapy. Expert Opin Ther Targets 2012;16(1):49-66
   PubMed Web of Science ®Google Scholar
• Huang FT, Zhuan-Sun YX, Zhuang YY, et al. Inhibition of hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance. Int J Oncol 2012;41(5):1707-14
   PubMed Web of Science ®Google Scholar
• Fu J, Rodova M, Roy SK, et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett 2013;330(1):22-32
   PubMed Web of Science ®Google Scholar
• Guo J, Gao J, Li Z, et al. Adenovirus vector-mediated Gli1 siRNA induces growth inhibition and apoptosis in human pancreatic cancer with Smo-dependent or Smo-independent Hh pathway activation in vitro and in vivo. Cancer Lett 2013;339(2):185-94
   PubMed Web of Science ®Google Scholar
• Xin Y, Shen XD, Cheng L, et al. Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency. Cancer Chemother Pharmacol 2014;73(4):711-19
   PubMed Web of Science ®Google Scholar
• Huang M, Tang SN, Upadhyay G, et al. Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting Akt and Sonic hedgehog pathways. PLoS One 2014;9(4):e92161
   PubMed Web of Science ®Google Scholar
• Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 2003;3(10):756-67
   PubMed Web of Science ®Google Scholar
• Bao B, Wang Z, Ali S, et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011;307(1):26-36
   PubMed Web of Science ®Google Scholar
• Wend P, Holland JD, Ziebold U, et al. Wnt signaling in stem and cancer stem cells. Semin Cell Dev Biol 2010;21(8):855-63
   PubMed Web of Science ®Google Scholar
• Vermeulen L, De Sousa E Melo F, van der Heijden M, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010;12(5):468-76
   PubMed Web of Science ®Google Scholar
• Cui J, Jiang W, Wang S, et al. Role of Wnt/beta-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des 2012;18(17):2464-71
   PubMed Web of Science ®Google Scholar
• Farhana L, Dawson MI, Das JK, et al. Adamantyl retinoid-related molecules induce apoptosis in pancreatic cancer cells by inhibiting IGF-1R and Wnt/beta-catenin pathways. J Oncol 2012;2012:796729
   Google Scholar
• Iacobuzio-Donahue CA, Ryu B, Hruban RH, et al. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol 2002;160(1):91-9
   PubMed Web of Science ®Google Scholar
• Apte MV, Wilson JS. Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells. J Gastroenterol Hepatol 2012;27(Suppl 2):69-74
   PubMedGoogle Scholar
• Whatcott C, Han H, Posner RG, et al. Tumor-stromal interactions in pancreatic cancer. Crit Rev Oncog 2013;18(1-2):135-51
   PubMedGoogle Scholar
• Neesse A, Krug S, Gress TM, et al. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther 2013;7:33-43
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Von Hoff DD. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res 2012;18(16):4249-56
   PubMed Web of Science ®Google Scholar
• Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324(5933):1457-61
   PubMed Web of Science ®Google Scholar
• Jimeno A, Weiss GJ, Miller WH, et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res 2013;19(10):2766-74
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17(8):2502-11
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29(34):4548-54
   PubMed Web of Science ®Google Scholar
• Frese KK, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2012;2(3):260-9
   PubMed Web of Science ®Google Scholar
• Neesse A, Frese KK, Chan DS, et al. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut 2014;63(6):974-83
   PubMed Web of Science ®Google Scholar
• Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008;455(7211):406-10
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Pradhan RN, Sarkar RR. Structural and logical analysis of a comprehensive hedgehog signaling pathway to identify alternative drug targets for glioma, colon and pancreatic cancer. PLoS One 2013;8(7):e69132
   Google Scholar
• Yamasaki A, Kameda C, Xu R, et al. Nuclear factor kappaB-activated monocytes contribute to pancreatic cancer progression through the production of Shh. Cancer Immunol Immunother 2010;59(5):675-86
   PubMed Web of Science ®Google Scholar
• Singh AP, Arora S, Bhardwaj A, et al. CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor kappaB: implications for bidirectional tumor-stromal interactions. J Biol Chem 2012;287(46):39115-24
   PubMed Web of Science ®Google Scholar
• Hwang RF, Moore TT, Hattersley MM, et al. Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer. Mol Cancer Res 2012;10(9):1147-57
   PubMed Web of Science ®Google Scholar
• Lonardo E, Frias-Aldeguer J, Hermann PC, et al. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle 2012;11(7):1282-90
   PubMed Web of Science ®Google Scholar
• Onishi H, Kai M, Odate S, et al. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Sci 2011;102(6):1144-50
   PubMed Web of Science ®Google Scholar
• Lei J, Ma J, Ma Q, et al. Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner. Mol Cancer 2013;12:66
   PubMed Web of Science ®Google Scholar
• Spivak-Kroizman TR, Hostetter G, Posner R, et al. Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res 2013;73(11):3235-47
   PubMed Web of Science ®Google Scholar
• Onishi H, Morifuji Y, Kai M, et al. Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer. Cancer Sci 2012;103(7):1272-9
   PubMed Web of Science ®Google Scholar
• Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013;62(1):112-20
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Harris WP, Beck JT, et al. A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer. J Clin Oncol 2013;31(Suppl):abstract 4010
   Google Scholar
• Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007;67(19):9518-27
   PubMed Web of Science ®Google Scholar
• Kurahara H, Shinchi H, Mataki Y, et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 2011;167(2):e211-19
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Yanagimoto H, Satoi S, et al. Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas 2012;41(3):409-15
   PubMed Web of Science ®Google Scholar
• Ikemoto T, Yamaguchi T, Morine Y, et al. Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas 2006;33(4):386-90
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006;12(18):5423-34
   PubMed Web of Science ®Google Scholar
• Tjomsland V, Spångeus A, Sandström P, et al. Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor. PLoS One 2010;5(10):e13441
   Google Scholar
• Sideras K, Braat H, Kwekkeboom J, et al. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev 2014;40(4):513-22
   PubMed Web of Science ®Google Scholar
• Gunturu KS, Rossi GR, Saif MW. Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol 2013;5(1):81-9
   PubMed Web of Science ®Google Scholar
• Pour PM, Raha CR. Pancreatic carcinogenic effect of N-nitrosobis (2-oxobutyl) amine and N-nitroso (2-oxobutyl) (2-oxopropyl) amine in Syrian hamster. Cancer Lett 1981;12(3):223-9
   PubMed Web of Science ®Google Scholar
• Hennig R, Ventura J, Segersvard R, et al. LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. Neoplasia 2005;7(4):417-25
   PubMed Web of Science ®Google Scholar
• Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006;103(15):5947-52
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7(5):469-83
   PubMed Web of Science ®Google Scholar
• Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225(5):621-33; discussion 33-6
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297(3):267-77
   PubMed Web of Science ®Google Scholar
• Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013;310(14):1473-81
   PubMed Web of Science ®Google Scholar
• Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299(9):1019-26
   PubMed Web of Science ®Google Scholar
• Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981;48(8):1705-10
   PubMed Web of Science ®Google Scholar
• Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15(6):2403-13
   PubMed Web of Science ®Google Scholar
• Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24(24):3946-52
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27(33):5513-18
   PubMed Web of Science ®Google Scholar
• Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007;25(30):4787-92
   PubMed Web of Science ®Google Scholar
• Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011;47(11):1676-81
   PubMed Web of Science ®Google Scholar
• Maire F, Sauvanet A. Palliation of biliary and duodenal obstruction in patients with unresectable pancreatic cancer: endoscopy or surgery? J Visc Surg 2013;150(3 Suppl):S27-31
   Google Scholar
• Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 2007;110(4):738-44
   PubMed Web of Science ®Google Scholar
• Krop I, Demuth T, Guthrie T, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 2012;30(19):2307-13
   PubMed Web of Science ®Google Scholar
• Wedén S, Klemp M, Gladhaug IP, et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 2011;128(5):1120-8
   PubMed Web of Science ®Google Scholar
• Rong Y, Qin X, Jin D, et al. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin Exp Med 2012;12(3):173-80
   PubMed Web of Science ®Google Scholar
• Kawaoka T, Oka M, Takashima M, et al. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Oncol Rep 2008;20(1):155-63
   PubMed Web of Science ®Google Scholar
• Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013;36(7):382-9
   PubMed Web of Science ®Google Scholar
• Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010;33(8):828-33
   PubMed Web of Science ®Google Scholar
• Rasku MA, Clem AL, Telang S, et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008;6:12
   PubMed Web of Science ®Google Scholar
• Leao IC, Ganesan P, Armstrong TD, et al. Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. Clin Transl Sci 2008;1(3):228-39
   PubMed Web of Science ®Google Scholar